TERRASCEND CORP (TSND.CA) Fundamental Analysis & Valuation

TSX:TSND • CA88105E1088

0.87 CAD
-0.06 (-6.45%)
Last: Mar 10, 2026, 07:00 PM

This TSND.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, TSND scores 3 out of 10 in our fundamental rating. TSND was compared to 34 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TSND have multiple concerns. TSND is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. TSND.CA Profitability Analysis

1.1 Basic Checks

  • TSND had negative earnings in the past year.
  • TSND had a positive operating cash flow in the past year.
  • TSND had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: TSND reported negative operating cash flow in multiple years.
TSND.CA Yearly Net Income VS EBIT VS OCF VS FCFTSND.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -21.71%, TSND is doing worse than 64.71% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -128.44%, TSND is doing worse than 73.53% of the companies in the same industry.
  • TSND's Return On Invested Capital of 5.70% is amongst the best of the industry. TSND outperforms 82.35% of its industry peers.
Industry RankSector Rank
ROA -21.71%
ROE -128.44%
ROIC 5.7%
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TSND.CA Yearly ROA, ROE, ROICTSND.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

  • The Operating Margin of TSND (13.76%) is better than 76.47% of its industry peers.
  • TSND's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 51.29%, TSND is doing good in the industry, outperforming 70.59% of the companies in the same industry.
  • In the last couple of years the Gross Margin of TSND has grown nicely.
Industry RankSector Rank
OM 13.76%
PM (TTM) N/A
GM 51.29%
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
TSND.CA Yearly Profit, Operating, Gross MarginsTSND.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

3

2. TSND.CA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TSND is destroying value.
  • Compared to 1 year ago, TSND has more shares outstanding
  • TSND has more shares outstanding than it did 5 years ago.
  • TSND has a worse debt/assets ratio than last year.
TSND.CA Yearly Shares OutstandingTSND.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
TSND.CA Yearly Total Debt VS Total AssetsTSND.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -1.06, we must say that TSND is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of TSND (-1.06) is comparable to the rest of the industry.
  • The Debt to FCF ratio of TSND is 22.68, which is on the high side as it means it would take TSND, 22.68 years of fcf income to pay off all of its debts.
  • TSND has a better Debt to FCF ratio (22.68) than 61.76% of its industry peers.
  • TSND has a Debt/Equity ratio of 2.26. This is a high value indicating a heavy dependency on external financing.
  • TSND has a Debt to Equity ratio of 2.26. This is in the lower half of the industry: TSND underperforms 79.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.26
Debt/FCF 22.68
Altman-Z -1.06
ROIC/WACC0.57
WACC9.99%
TSND.CA Yearly LT Debt VS Equity VS FCFTSND.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • TSND has a Current Ratio of 1.56. This is a normal value and indicates that TSND is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.56, TSND is in line with its industry, outperforming 50.00% of the companies in the same industry.
  • TSND has a Quick Ratio of 1.12. This is a normal value and indicates that TSND is financially healthy and should not expect problems in meeting its short term obligations.
  • TSND's Quick ratio of 1.12 is in line compared to the rest of the industry. TSND outperforms 50.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.56
Quick Ratio 1.12
TSND.CA Yearly Current Assets VS Current LiabilitesTSND.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

4

3. TSND.CA Growth Analysis

3.1 Past

  • The earnings per share for TSND have decreased strongly by -25.00% in the last year.
  • The Revenue for TSND has decreased by -13.62% in the past year. This is quite bad
  • Measured over the past years, TSND shows a very strong growth in Revenue. The Revenue has been growing by 36.80% on average per year.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)-13.62%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-12.22%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.08% on average over the next years. This is quite good.
  • TSND is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.38% yearly.
EPS Next Y24.44%
EPS Next 2Y33.17%
EPS Next 3Y22.74%
EPS Next 5Y13.08%
Revenue Next Year-14.31%
Revenue Next 2Y-6.8%
Revenue Next 3Y-3.31%
Revenue Next 5Y0.38%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TSND.CA Yearly Revenue VS EstimatesTSND.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
TSND.CA Yearly EPS VS EstimatesTSND.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -0.2 -0.4 -0.6 -0.8 -1

2

4. TSND.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • TSND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSND. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSND.CA Price Earnings VS Forward Price EarningsTSND.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TSND indicates a somewhat cheap valuation: TSND is cheaper than 76.47% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of TSND indicates a somewhat cheap valuation: TSND is cheaper than 64.71% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 24.3
EV/EBITDA 7.65
TSND.CA Per share dataTSND.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TSND's earnings are expected to grow with 22.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.17%
EPS Next 3Y22.74%

0

5. TSND.CA Dividend Analysis

5.1 Amount

  • No dividends for TSND!.
Industry RankSector Rank
Dividend Yield 0%

TSND.CA Fundamentals: All Metrics, Ratios and Statistics

TERRASCEND CORP

TSX:TSND (3/10/2026, 7:00:00 PM)

0.87

-0.06 (-6.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners39.05%
Inst Owner ChangeN/A
Ins Owners6.68%
Ins Owner ChangeN/A
Market Cap323.66M
Revenue(TTM)275.46M
Net Income(TTM)-120.56M
Analysts82.22
Price Target1.79 (105.75%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-481.28%
Min EPS beat(2)-614.39%
Max EPS beat(2)-348.18%
EPS beat(4)0
Avg EPS beat(4)-310.68%
Min EPS beat(4)-614.39%
Max EPS beat(4)-20.66%
EPS beat(8)0
Avg EPS beat(8)-308.43%
EPS beat(12)1
Avg EPS beat(12)-207.87%
EPS beat(16)2
Avg EPS beat(16)-327.17%
Revenue beat(2)0
Avg Revenue beat(2)-4.75%
Min Revenue beat(2)-6.15%
Max Revenue beat(2)-3.35%
Revenue beat(4)0
Avg Revenue beat(4)-3.84%
Min Revenue beat(4)-6.15%
Max Revenue beat(4)-2.6%
Revenue beat(8)0
Avg Revenue beat(8)-4.34%
Revenue beat(12)2
Avg Revenue beat(12)-3.04%
Revenue beat(16)2
Avg Revenue beat(16)-5.41%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.29%
Revenue NQ rev (1m)-0.54%
Revenue NQ rev (3m)-1.03%
Revenue NY rev (1m)-0.32%
Revenue NY rev (3m)-0.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.87
P/FCF 24.3
P/OCF 10.27
P/B 2.54
P/tB N/A
EV/EBITDA 7.65
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)0.04
FCFY4.11%
OCF(TTM)0.08
OCFY9.74%
SpS1
BVpS0.34
TBVpS-0.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.71%
ROE -128.44%
ROCE 7.91%
ROIC 5.7%
ROICexc 6.18%
ROICexgc 17.05%
OM 13.76%
PM (TTM) N/A
GM 51.29%
FCFM 3.57%
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-2.11%
ROICexgc growth 5YN/A
ROICexc growth 3Y1.66%
ROICexc growth 5YN/A
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
F-Score6
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 2.26
Debt/FCF 22.68
Debt/EBITDA 3.83
Cap/Depr 77.06%
Cap/Sales 4.88%
Interest Coverage 1.43
Cash Conversion 42.03%
Profit Quality N/A
Current Ratio 1.56
Quick Ratio 1.12
Altman-Z -1.06
F-Score6
WACC9.99%
ROIC/WACC0.57
Cap/Depr(3y)90.87%
Cap/Depr(5y)192.32%
Cap/Sales(3y)7.77%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y24.44%
EPS Next 2Y33.17%
EPS Next 3Y22.74%
EPS Next 5Y13.08%
Revenue 1Y (TTM)-13.62%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-12.22%
Revenue Next Year-14.31%
Revenue Next 2Y-6.8%
Revenue Next 3Y-3.31%
Revenue Next 5Y0.38%
EBIT growth 1Y14.74%
EBIT growth 3Y6.79%
EBIT growth 5YN/A
EBIT Next Year158.48%
EBIT Next 3Y40.49%
EBIT Next 5Y29.78%
FCF growth 1Y227.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.28%
OCF growth 3YN/A
OCF growth 5YN/A

TERRASCEND CORP / TSND.CA FAQ

What is the fundamental rating for TSND stock?

ChartMill assigns a fundamental rating of 3 / 10 to TSND.CA.


Can you provide the valuation status for TERRASCEND CORP?

ChartMill assigns a valuation rating of 2 / 10 to TERRASCEND CORP (TSND.CA). This can be considered as Overvalued.


What is the profitability of TSND stock?

TERRASCEND CORP (TSND.CA) has a profitability rating of 3 / 10.


How financially healthy is TERRASCEND CORP?

The financial health rating of TERRASCEND CORP (TSND.CA) is 3 / 10.


What is the earnings growth outlook for TERRASCEND CORP?

The Earnings per Share (EPS) of TERRASCEND CORP (TSND.CA) is expected to grow by 24.44% in the next year.